Incoming ethical issues for deep brain stimulation: when long-term treatment leads to a ‘new form of the disease’

Deep brain stimulation (DBS) has been regarded as an efficient and safe treatment for Parkinson’s disease (PD) since being approved by the Food and Drug Administration (FDA) in 1997. It is estimated that more than 150 000 patients have been implanted, with a forecasted rapid increase in uptake with...

Full description

Saved in:  
Bibliographic Details
Authors: Gilbert, Frederic (Author) ; Lancelot, Mathilde (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2021
In: Journal of medical ethics
Year: 2021, Volume: 47, Issue: 1, Pages: 20-25
Online Access: Presumably Free Access
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1816164011
003 DE-627
005 20230428063545.0
007 cr uuu---uuuuu
008 220908s2021 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2019-106052  |2 doi 
035 |a (DE-627)1816164011 
035 |a (DE-599)KXP1816164011 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Gilbert, Frederic  |e VerfasserIn  |4 aut 
245 1 0 |a Incoming ethical issues for deep brain stimulation: when long-term treatment leads to a ‘new form of the disease’ 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Deep brain stimulation (DBS) has been regarded as an efficient and safe treatment for Parkinson’s disease (PD) since being approved by the Food and Drug Administration (FDA) in 1997. It is estimated that more than 150 000 patients have been implanted, with a forecasted rapid increase in uptake with population ageing. Recent longitudinal follow-up studies have reported a significant increase in postoperative survival rates of patients with PD implanted with DBS as compared with those not implanted with DBS. Although DBS tends to increase life expectancy for most patients with PD, this medical benefit does not come without attendant negative consequences. For example, emerging forms of iatrogenic harms are sometimes induced—harms which were not initially expected when clinicians proposed neurosurgery and patients or their guardians consented to the treatment. We report and discuss the clinical case of a patient who was implanted with DBS more than 20 years ago (at the time of writing) and is now experiencing unexpected stages of PD. This case illustrates how extending the life span without improving quality of life may introduce a burden of harms for patients and families. As well, this case shows why we should prepare for the expanding numbers of PD-implanted patients experiencing a gain of longevity but with severe stages of disease leading to diminution in quality of life. This newly observed effect of DBS treatment requires us to explore ethical questions related to iatrogenic harms, informed consent, end of life and caregivers’ burden. 
700 1 |a Lancelot, Mathilde  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 47(2021), 1, Seite 20-25  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:47  |g year:2021  |g number:1  |g pages:20-25 
856 |u https://hal.science/hal-03735041/file/Gilbert%20et%20Lancelot%202020%20Version%20auteurs.pdf  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h repository [oa repository (via OAI-PMH doi match)] 
856 4 0 |u https://doi.org/10.1136/medethics-2019-106052  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/47/1/20.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 418561795X 
LOK |0 003 DE-627 
LOK |0 004 1816164011 
LOK |0 005 20220908053757 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#8A0639D44CDD0D0380D86FBB72D2BE8471EB5858 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw